On December 10, 2020 Excyte Biopharma reported the company has completed a round A financing of tens of millions of yuan, which was jointly led by Detong Capital and Qianhai Master Fund (Press release, Excyte Biopharma, DEC 10, 2020, View Source;lang=en [SID1234646272]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On December 10, 2020 Onxeo S.A. (ISIN: FR0010095596), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, reported the transfer of the listing of its shares from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility on December 15, 2020 (Press release, Onxeo, DEC 10, 2020, View Source [SID1234575005]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The application for the admission of Onxeo’s shares to the Euronext Growth market in Paris was approved by the Euronext Admissions Committee on December 9, 2020.

As a reminder, Onxeo had announced on July 29, 2010 its intention to transfer the listing of its shares to the Euronext Growth Paris multilateral trading facility. The transfer to Euronext Growth Paris is intended to enable Onxeo to be listed on a market more appropriate to the size of the company, to reduce the costs associated with listing, while enabling it to continue to benefit from the attractions of the financial markets.

Onxeo will continue to provide accurate, precise and truthful information, making public any inside information concerning the company, in accordance with the European Regulation on Market Abuse (MAR Regulation).

Final timetable for the transfer of listing market

The company is supported in its project of transfer to Euronext Growth by Invest Securities as Listing Sponsor.

Wednesday, December 9, 2020 - Notification by Euronext of the decision to admit the securities to Euronext Growth
Thursday, December 10, 2020 - Distribution of a press release by the Company

Friday, December 11, 2020

– Posting of the Information Document on the websites of the Company and Euronext
– Distribution of a Euronext market notice announcing the delisting of ordinary shares of Onxeo from Euronext Paris

– Distribution of a Euronext market notice announcing the admission of ordinary shares of Onxeo to Euronext Growth

Monday, December 14, 2020 - Delisting of ordinary shares of Onxeo from Euronext Paris (post-market)
Tuesday, December 15, 2020 - Admission of ordinary shares of Onxeo to Euronext Growth (at opening)
The ISIN code for identifying Onxeo securities remains unchanged (FR0010095596) and the mnemonic becomes ALONX.

In addition, Onxeo shares remain eligible for PEAs and PEA-SMEs.

The information document relating to the transfer of shares to Euronext Growth is available on the Company’s website: www.onxeo.com/investors-en/ on December 11, 2020.

On December 10, 2020 Bristol Myers Squibb (NYSE:BMY) reported that its Board of Directors has declared a quarterly dividend of forty-nine cents ($.49) per share on the $.10 par value common stock of the company (Press release, Bristol-Myers Squibb, DEC 10, 2020, View Source [SID1234573349]). The dividend is payable on February 1, 2021 to stockholders of record at the close of business on January 4, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This amount represents an 8.9% increase in the quarterly dividend over last year’s quarterly rate of forty-five cents ($.45) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2021 is $1.96 per share. This marks the twelfth consecutive fiscal year that Bristol Myers Squibb increased its dividend payouts.

In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable March 1, 2021 to stockholders of record at the close of business on February 2, 2021.

On December 10, 2020 QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN") reported certain terms of the new senior, unsecured net share settled convertible bonds, which may be converted, in part, into ordinary shares of QIAGEN ("Shares"), due 2027 (the "New Bonds") and results of the invitation to sell the outstanding 0.875% convertible notes due 2021 (ISIN: XS1046477581; the "2021 Notes") (Press release, Qiagen, DEC 10, 2020, View Source [SID1234572985]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The New Bonds Offering

The size of the offering has been increased to $500 million aggregate principal amount. The New Bonds will be issued at 100% of their principal amount, will bear no interest and, unless previously converted, redeemed or repurchased and cancelled, will be redeemed at par value. The initial conversion price will be set at a 55% premium over the reference share price. The reference share price will be equal to the arithmetic average of the daily volume weighted average prices of the Shares on the 2 consecutive trading days commencing on December 10, 2020 on the New York Stock Exchange.

The final terms of the New Bonds will be announced following the determination of the reference share price, expected to occur post close of trading on the New York Stock Exchange on December 11, 2020.

Under the terms of the New Bonds offering, QIAGEN will agree not to sell any securities that are substantially similar to the New Bonds or its Shares for a lock-up period ending 90 days following the settlement date, subject to certain exceptions and waiver by BofA Securities, Deutsche Bank Aktiengesellschaft and Goldman Sachs International as Joint Global Coordinators.

The Invitation to Sell the 2021 Notes

As at the close of the bookbuilding process, QIAGEN announces it has agreed to purchase $172.4 million in aggregate principal amount of the outstanding 2021 Notes.

Following the completion of the repurchase, an aggregate principal amount of $4.8 million will remain outstanding.

In respect of 2021 Notes accepted for purchase, QIAGEN will pay a purchase price per 2021 Note equal to the arithmetic average of each of the daily volume weighted average prices of the Shares on the New York Stock Exchange, multiplied by the prevailing conversion ratio applicable on each such day, on the 2 consecutive trading days commencing on December 10, 2020.

On December 10, 2020, Propanc Biopharma, Inc. (the "Company") reported that it entered into a securities purchase agreement (the "Purchase Agreement") with GW Holdings Group, LLC ("GW"), pursuant to which GW purchased a convertible redeemable promissory note (the "December 2020 GW Note") from the Company in the aggregate principal amount of $131,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of GW. The transaction contemplated by the Purchase Agreement closed on or about December 10, 2020 (Filing, 8-K, Propanc, DEC 10, 2020, View Source [SID1234572943]). The Company intends to use the net proceeds ($125,000) from the December 2020 GW Note for general working capital purposes. Pursuant to the terms of the Purchase Agreement, the Company paid GW’s legal fees and expenses in the aggregate amount of $6,000.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Purchase Agreement contains such representations, warranties and covenants as are typical for a transaction of this nature.

The maturity date of the December 2020 GW Note is December 10, 2021 (the "Maturity Date"). The December 2020 GW Note shall bear interest at a rate of 8% per annum, which interest may be paid by the Company to GW in shares of common stock, but shall not be payable until the December 2020 GW Note becomes payable, whether at the Maturity Date or upon acceleration or by prepayment, as described below. GW has the option to convert all or any amount of the principal face amount of the December 2020 GW Note, starting on June 18, 2021 and ending on the Maturity Date. The December 2020 GW Note may be converted into shares of the Company’s common stock equal to 40% discount of the lowest closing bid price of the common stock for the ten trading days immediately prior to the delivery of a notice of conversion, provided, however, such conversion shall not be effected to the extent that GW together with any of its affiliates would beneficially own in excess of 4.99%, which may be increased up to 9.99% upon 61 days’ prior written notice by GW to the Company. The Company may redeem the December 2020 GW Note as follows: (i) if the redemption occurs within the first 60 days, then an amount equal to 115% of the face amount of the note plus any accrued interest, (ii) if the redemption occurs after the 61st day but on or before the 120th day following the issuance of the note, then an amount equal to 125% of the face amount of the note along with any accrued interest, (iii) if the redemption occurs after the 121st day but on or before the 180th day following the issuance of the note, then an amount equal to 135% of the face amount of the note along with any accrued interest.

In the event of a default, without demand, presentment or notice, the December 2020 GW Note shall become immediately due and payable.

Other than as described above, the December 2020 GW Note contains certain events of default, including failure to timely issue shares upon receipt of a notice of conversion, as well as certain customary events of default, including, among others, breach of covenants, representations or warranties, insolvency, bankruptcy, liquidation and failure by the Company to pay the principal and interest due under the December 2020 GW Note.

The foregoing description of the Purchase Agreement and the December 2020 GW Note does not purport to be complete and is qualified in their entirety by reference to the full text of the Purchase Agreement and the December 2020 GW Note, which are filed as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.